Navigation Links
Neurocrine Biosciences Reports Third Quarter 2009 Results
Date:10/28/2009

ollaborators for development, commercial manufacturing and marketing and sales activities. In addition, the Company faces risks and uncertainties with respect to the Company's R & D pipeline including risk that the Company's urocortin 2, and VMAT2 clinical candidates will not proceed to later stage clinical trials, and risk that the Company's research programs will not identify pre-clinical candidates for further development. With respect to its pipeline overall, the Company faces risk that it will be unable to raise additional funding required to complete development of all of its product candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate collaborators for commercial manufacturing and marketing and sales activities; uncertainties relating to patent protection and intellectual property rights of third parties; risks and uncertainties relating to competitive products and technological changes that may limit demand for the Company's products; and the other risks described in the Company's report on Form 10-K for the year ended December 31, 2008 and Form 10-Q for the quarter ended June 30, 2009. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.

                          NEUROCRINE BIOSCIENCES, INC.
               CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                  (in thousands, except loss per share data)


                                        Three Months Ended   Nine Months Ended
                                           September 30,       September 30,
                                           -------------       -------------
                                           2009      2008      2009      2008
                                           ----      ----      ----      ----
                                            (unaudited)          (unaudited
'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2009 Financial Results
2. Neurocrine Biosciences Presents Elagolix Data
3. Neurocrine Announces Top-Line Results From 702 Study (Lilac PETAL Study) of Elagolix for Treatment of Endometriosis Pain
4. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
5. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
6. Neurocrine Biosciences Reports First Quarter 2008 Results
7. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
8. Sangamo BioSciences Announces Research Collaboration With UCLA in Human Stem Cells Selected to Receive Clinical Research Award
9. Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
10. Signum Biosciences Awarded Phase II SBIR Grant by the NIH for the Treatment of Rosacea
11. Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014 WHEN: Wednesday, October ... complimentary registration available at: http://bit.ly/1yStiU9 ... Vidyasekar and Visionary Innovation Research Group Senior ... electricity, self-assembling materials, nanobots and flexible electronics ... will transform our lives in the coming ...
(Date:10/22/2014)... LA JOLLA, Calif. , Oct. 22, ... RGLS ), a biopharmaceutical company leading ... targeting microRNAs, today announced that it has ... from an ongoing clinical study evaluating RG-101, ... for the treatment of hepatitis C virus ...
(Date:10/20/2014)... ENGLEWOOD, Colo. , Oct. 20, 2014 /PRNewswire/ ... Inc. (NYSE MKT: AMPE), today announced that its ... the clinical and research potential for its novel ... oxidation-reduction potential (ORP) in the body in response ... clinical value of ORP as a clinical marker ...
Breaking Medicine Technology:Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5
... Feb. 23, 2011 Reportlinker.com announces that a ... catalogue: Global Medical Ultrasound ... This report analyzes the worldwide ... by the following end use segments: Radiology, Cardiology, ...
... Calif., Feb. 23, 2011 Omnicell, Inc ., ... medication management systems to healthcare facilities, today announced the ... healthcare executives were polled to identify trends in requirements ... decisions. The survey found that the majority of hospitals ...
Cached Medicine Technology:Reportlinker Adds Global Medical Ultrasound Equipment Industry 275 Percent of Hospital IT Leaders View Interoperability Between Vendor Systems as Critical to Operational Effectiveness in Healthcare Settings 2
(Date:10/22/2014)... During the Western United States’ worst ... dangerously low, Southern Oregon’s water is proving resistant to ... lowest mountain snow pack on record in 2014, remain ... autumn.* That was the observation of journalist-hikers Art Bernstein ... Southern Oregon,” during an interview with water advocate Sharon ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Losing Weight Your ... industry is staring you in the face, it certainly can ... not do your body an extra favor by doing it ... tempting crash diets. Instead, listen to your body, exercise regularly, ... Exercise is essential to losing weight; you need to exercise ...
(Date:10/22/2014)... Richard Carlson, Managing Partner of Blue ... over 25 years experience. Mr. Carlson is a ... related to EDI, B2B Commerce, RFID and Internet/Intranet technology. ... Board member for Pharmaceutical Commerce Magazine and a Gerson ... is a management and technology consulting firm focused solely ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, ... (IVF) are only about half as likely as white women ... research indicates, and the racial disparity persists even when donor ... of white patients became pregnant after IVF, compared to about ... IVF cycles over two years to tease out the impact ...
(Date:10/22/2014)... By Maureen Salamon ... -- A crucial part of conventional in vitro fertilization (IVF) ... can instead take place in a device inside the vagina, ... Colombia contend that the device, called an INVOcell, might sharply ... could also make the technology more accessible to those who ...
Breaking Medicine News(10 mins):Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4
... SEGUNDO, Calif., Nov. 3 DaVita Inc. (NYSE:,DVA) ... 30, 2008. Net,income for the three and nine ... $275.8 million, or $0.89 per share and $2.59 ... Net income for the three months ended September ...
... say a home safety review could cut odds of fractures ... News) -- Former first lady Nancy Reagan and Democratic ... hip injuries. And on Friday, author Studs Terkel died, following ... decline. , Such news, experts say, should be a reminder ...
... be changed , , SATURDAY, Nov. 1 (HealthDay News) -- ... according to a UCLA study of almost 1,500 patients ... and need to be treated accordingly. , The UCLA ... approach needs to be changed. , "We have shown ...
... American Academy of Otolaryngology Head and Neck ... guideline to help healthcare practitioners identify and treat ... of the most common underlying conditions that cause ... BPPV, the most common vestibular (inner ear) disorder ...
... Entrees Provide Easy, Delicious, Relief During ... Stressful Election Times, EDISON, N.J., Oct. ... isn,t much time to think about what to eat,let alone cook an ... stress with their delicious and easy gourmet,Indian cuisine that can be made ...
... wardrobe could have been spent on ... healthcare, housing, ... the http://www.DressLikePalin.com website this week, scores offering,their views on ... National Committee famously spent on the wardrobe for Gov. Sarah,Palin., ...
Cached Medicine News:Health News:DaVita 3rd Quarter 2008 Results 2Health News:DaVita 3rd Quarter 2008 Results 3Health News:DaVita 3rd Quarter 2008 Results 4Health News:DaVita 3rd Quarter 2008 Results 5Health News:DaVita 3rd Quarter 2008 Results 6Health News:DaVita 3rd Quarter 2008 Results 7Health News:DaVita 3rd Quarter 2008 Results 8Health News:DaVita 3rd Quarter 2008 Results 9Health News:DaVita 3rd Quarter 2008 Results 10Health News:DaVita 3rd Quarter 2008 Results 11Health News:DaVita 3rd Quarter 2008 Results 12Health News:DaVita 3rd Quarter 2008 Results 13Health News:DaVita 3rd Quarter 2008 Results 14Health News:DaVita 3rd Quarter 2008 Results 15Health News:DaVita 3rd Quarter 2008 Results 16Health News:DaVita 3rd Quarter 2008 Results 17Health News:Falls Are Leading Cause of Injury to Seniors 2Health News:Tailored Treatment Boosts Kidney Cancer Survival 2Health News:ENT doctors release national guideline on treatment for common cause of dizziness 2Health News:ENT doctors release national guideline on treatment for common cause of dizziness 3Health News:Easy Ethnic Election 2Health News:Tens of Thousands View DressLikePalin Web Site 2Health News:Tens of Thousands View DressLikePalin Web Site 3
Non-dissolvable Herrick Lacrimal Plugs provide long-term lacrimal occlusion through partial blockage of the horizontal canaliculus....
10 (mm) smooth platform; Serrated handle in stainless steel....
... first digital solution designed specifically for cardiologists ... outside cardiology. From the server core to ... combined expertise in both cine film and ... work the way they want, wherever they ...
... Medison SonoAce 9900 is ... based ultrasound system, with ... is DICOM compatible, designed ... general imaging, obstetrics, gynecology, ...
Medicine Products: